Health Canada Approves Zoetis’ Portela for Feline OA Pain
PARSIPPANY, N.J., December 5, 2025 — Zoetis Inc. announced that Health Canada has approved Portela™ (relfovetmab injection) for the...
AI drug discovery Alzheimer’s Disease artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biotechnology Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology oncology innovation Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory compliance targeted therapy
PARSIPPANY, N.J., December 5, 2025 — Zoetis Inc. announced that Health Canada has approved Portela™ (relfovetmab injection) for the...
Parsippany, New Jersey / Brussels, October 29, 2025 — Zoetis Inc. today announced that the European Commission has granted...
